GeneDx
Yahoo Finance • 12 months ago
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Evercore ISI... Full story
Yahoo Finance • last year
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STAMFORD, Conn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of November 17, 2023, the compensation committee of Gene... Full story
Yahoo Finance • last year
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the third quarter of 20... Full story
Yahoo Finance • last year
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
STAMFORD, Conn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced a monumental accomplishment in its ongoing commitment to deliver personali... Full story
Yahoo Finance • last year
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
STAMFORD, Conn., Aug. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Genetics in Medicine, the official journal of the American College of... Full story
Yahoo Finance • last year
GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium
STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new data on urine mitochondrial DNA testing a... Full story
Yahoo Finance • last year
GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants
New paperpublished todayin Nature Methodsdescribesthe PanGenome Research-Tool Kit for analyzingcomplex regions of the human pangenome Recently released human pangenomebetter represents landscape of diverse human populations STAMFORD, Con... Full story
Yahoo Finance • last year
GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients
STAMFORD, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, applauds the decisions by the states of Florida and Arizona to provide rWGS f... Full story
Yahoo Finance • 2 years ago
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
STAMFORD, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced the availability of its GenomeXpress® and GenomeSeqDx® whole g... Full story
Yahoo Finance • 2 years ago
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
STAMFORD, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a clarification regarding the CUSIP number for the Company’s p... Full story
Yahoo Finance • 2 years ago
GeneDx Announces Reverse Stock Split
STAMFORD, Conn., April 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that its board of directors has approved a 1-for-33 reverse... Full story
Yahoo Finance • 2 years ago
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
STAMFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the first quarter of 2... Full story
Yahoo Finance • 2 years ago
GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Financial results are in line with previously announced preliminary 2022 results; Reiterating 2023 guidance, including total revenue of $205-220 million Completed financing in January 2023 with $150 million in expected proceeds; fully fun... Full story
Yahoo Finance • 2 years ago
GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference
STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate at the Cowen 43rd A... Full story
Yahoo Finance • 2 years ago
GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023
STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter and... Full story
Yahoo Finance • 2 years ago
GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering
STAMFORD, Conn., Jan. 31, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the closing of its previously announced underwritten public offering of shares of its Class A common stock (the “Underwritten Offering... Full story
Yahoo Finance • 2 years ago
GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery
Company submitted nearly one quarter of all candidate gene submissions to GeneMatcher in 2022 and collaborated on 63 publications involving new disease-gene associations or expansion of phenotype discoveries STAMFORD, Conn., Jan. 30, 202... Full story
Yahoo Finance • 2 years ago
GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering
STAMFORD, Conn., Jan. 27, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the pricing of offerings for an aggregate of 428,571,429 shares of its Class A common stock at a public offering price of $0.35 per sh... Full story
Yahoo Finance • 2 years ago
GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering
STAMFORD, Conn., Jan. 26, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it intends to commence an underwritten pu... Full story
